A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-564
- Sponsors Merck Sharp & Dohme
- 23 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research.
- 27 Nov 2018 Planned End Date changed from 12 Nov 2022 to 28 Dec 2025.